BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.
Authors: Kirsten R Müller-Vahl, Heidrun Prevedel, Karen Theloe, Hans Kolbe, et al
Neuropsychopharmacology, February 2003
—
Previous studies provide evidence that marijuana (Cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, there…
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Authors: Louise Arseneault, Mary Cannon, Richie Poulton, Robin Murray, Avshalom Caspi, Terrie E Moffitt
BMJ, 23 November 2002
—
The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…
Cardiovascular system effects of marijuana.
Authors: Reese T. Jones
The Journal of Clinical Pharmacology, November 2002
—
Marijuana and delta9-tetrahydrocannabinol (THC) increase heart rate, slightly increase supine blood pressure, and on occasion produce marked orthostatic hypotension. Cardiovascular effects in animals are different, with bradycardia and hypotension the most typical response. Ca…
Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.
Authors: Guy Neff, Christopher O’Brien, Rajender Reddy, Nora Bergasa, Arie Regev, et al
The American Journal of Gastroenterology, August 2002
—
Pruritus due to cholestatic liver disease can be particularly difficult to manage and frequently is intractable to a variety of medical therapies. The aim of our study is to evaluate the efficacy of delta-9-tetrahydrocannabinol (delta-9-THC) for intractable cholestatic related…
Response to Early AED Therapy and Its Prognostic Implications.
Authors: Jacqueline A. French
Epilepsy Currents, May 2002
—
Determining the prognosis of patients when they first present with epilepsy is a difficult task. Several clinical studies have shed light on this very important topic. Potential predictors of the refractory state, including seizure etiology, duration of epilepsy before treatme…
Cannabinoids and brain injury: therapeutic implications.
Authors: Raphael Mechoulam, David Panikashvili, Esther Shohami
Trends in Molecular Medicine, February 2002
—
Mounting in vitro and in vivo data suggest that the endocannabinoids anandamide and 2-arachidonoyl glycerol, as well as some plant and synthetic cannabinoids, have neuroprotective effects following brain injury. Cannabinoid receptor agonists inhibit glutamatergic synaptic tran…
Maternal use of cannabis and pregnancy outcome.
Authors: David M. Fergusson, L. John Horwood, Kate Northstone, ALSPAC Study Team
BJOG : an international journal of obstetrics and gynaecology, January 2002
—
OBJECTIVE: To document the prevalence of cannabis use in a large sample of British women studied during pregnancy, to determine the association between cannabis use and social and lifestyle factors and assess any independent effects on pregnancy outcome. DESIGN: Self-completed…
Chronic Cannabis Use in the Compassionate Investigational New Drug Program
Authors: Ethan Russo, Mary Lynn Mathre, Al Byrne, Robert Velin, Paul J. Bach, Juan Sanchez-Ramos, et al
Journal of Cannabis Therapeutics, 2002
—
The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic bepnefits and adverse effects of prolonged use of “medical marijuana” in a cohort of seriously ill patients. Use of cannabis was approved through the Compassionate Inves-tigational New…
A literature review of the consequences of prenatal marihuana exposure.
Authors: P.A. Fried, A.M. Smith
Neurotoxicology and teratology, January-February 2001
—
In spite of marihuana being the most widely used illegal drug among women of reproductive age, there is a relative paucity of literature dealing with the neurobehavioral consequences in offspring–particularly the longer-term effects. However, there is a degree of consistency…
Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Authors: Dominique Melck, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, et al
Endocrinology, January 2000
—
Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we rep…
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
Authors: Luciano De Petrocellis, Dominique Melck, Antonella Palmisano, Tiziana Bisogno, et al
PNAS, 7 July 1998
—
Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. Anandamide dose-dependently inhi…
Behavioral outcomes in preschool and school-age children exposed prenatally to marijuana: a review and speculative interpretation.
Authors: Peter A. Fried
NIDA research monograph, 1996
—
INTRODUCTION: In considering the relationship between marijuana use during pregnancy and the impact of such use upon the behavioral outcome of the young children of these pregnancies, the paucity of objective information is striking and, from one point of view, quite surprisin…